Table 4 Subgroup comparisons results of the meta-analysis

1

Female vs. male

Fix

1.17 [0.93, 1.48]

Chi² = 14.36, df = 10 (P = 0.16); I² = 30%

Z = 1.35 (P = 0.18)

2

White vs. other races

Fix

0.75 [0.48, 1.17]

Chi² = 1.32, df = 2 (P = 0.52); I² = 0%

Z = 1.26 (P = 0.21)

3

Smoke+ vs. Smoke−

Fix

1.10 [0.86, 1.40]

Chi² = 8.85, df = 7 (P = 0.26); I² = 21%

Z = 0.72 (P = 0.47)

4

Hypertension+ vs. Hypertension−

Fix

1.07 [0.80, 1.42]

Chi² = 5.33, df = 7 (P = 0.62); I² = 0%

Z = 0.43 (P = 0.66)

5

Hyperlipidemia+

vs. Hyperlipidemia−

Fix

1.13 [0.80, 1.60]

Chi² = 3.67, df = 7 (P = 0.82); I² = 0%

Z = 0.70 (P = 0.48)

6

Diabetes+ vs. Diabetes−

Fix

1.26 [0.98, 1.62]

Chi² = 12.07, df = 7 (P = 0.10); I² = 42%

Z = 1.83 (P = 0.07)

7

Depression+ vs. Depression−

Fix

1.36 [0.78, 2.39]

Chi² = 0.06, df = 1 (P = 0.80); I² = 0%

Z = 1.09 (P = 0.28)

8

Post MI+ vs. Post MI−

Fix

1.29 [1.00, 1.66]

Chi² = 1.85, df = 4 (P = 0.76); I² = 0%

Z = 1.95 (P = 0.05)

9

PTCA+ vs. PTCA−

Fix

0.88 [0.67, 1.16]

Chi² = 0.53, df = 2 (P = 0.77); I² = 0%

Z = 0.90 (P = 0.37)

10

CABG+ vs. CABG−

Random

1.59 [1.00, 2.52]

Tau² = 0.10; Chi² = 5.18, df = 2 (P = 0.07); I² = 61%

Z = 1.98 (P = 0.05)

11

Aspirn+ vs. Aspirin−

Fix

0.93 [0.65, 1.34]

Chi² = 0.34, df = 4 (P = 0.99); I² = 0%

Z = 0.36 (P = 0.72)

12

Other antiplatelet agent+

& Other antiplatelet agent−

Fix

1.21 [0.91, 1.61]

Chi² = 1.94, df = 2 (P = 0.38); I² = 0%

Z = 1.29 (P = 0.20)

13

ACEI+ vs. ACEI−

Fix

1.13 [0.87, 1.46]

Chi² = 2.12, df = 4 (P = 0.71); I² = 0%

Z = 0.92 (P = 0.36)

14

ARB+ vs. ARB−

Random

1.22 [0.53, 2.82]

Tau² = 0.26; Chi² = 3.53, df = 1 (P = 0.06); I² = 72%

Z = 0.46 (P = 0.64)

15

Beta-block+ vs. Beta-block−

Fix

1.05 [0.78, 1.41]

Chi² = 2.50, df = 5 (P = 0.78); I² = 0%

Z = 0.32 (P = 0.75)

16

CCB+ vs. CCB−

Fix

0.84 [0.58, 1.22]

Chi² = 0.78, df = 3 (P = 0.85); I² = 0%

Z = 0.92 (P = 0.36)

17

Statin+ vs. Statin−

Fix

1.18 [0.80, 1.75]

Chi² = 4.30, df = 5 (P = 0.51); I² = 0%

Z = 0.83 (P = 0.40)